Tvardi Therapeutics, Inc. - Asset Resilience Ratio
Tvardi Therapeutics, Inc. (TVRD) has an Asset Resilience Ratio of 19.87% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tvardi Therapeutics, Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Tvardi Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See Tvardi Therapeutics, Inc. (TVRD) balance sheet quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tvardi Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Tvardi Therapeutics, Inc..
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.13 Million | 19.87% |
| Total Liquid Assets | $5.13 Million | 19.87% |
Asset Resilience Insights
- Good Liquidity Position: Tvardi Therapeutics, Inc. maintains a healthy 19.87% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Tvardi Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Tvardi Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Tvardi Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.42% | $10.08 Million | $32.07 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $43.83 Million | -- |
| 2022-12-31 | 49.34% | $22.25 Million | $45.10 Million | -12.83pp |
| 2021-12-31 | 62.16% | $153.58 Million | $247.06 Million | +7.13pp |
| 2020-12-31 | 55.04% | $149.24 Million | $271.16 Million | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more